Bristol Goes In Big On New Valentine Nektar
Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.
You may also be interested in...
Following termination of its immuno-oncology partnership with Bristol, Nektar is paring operations, closing its India site and focusing on mid-stage NKTR-358, partnered with Lilly, and NKTR-255.
Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.